3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Statins are hypolipidemic drugs which not only improve cholesterol but also triglyceride levels. Whereas their cholesterol‐reducing effect involves inhibition of de novo biosynthesis of cellular cholesterol through competitive inhibition of its rate‐limiting enzyme 3‐hydroxy‐3‐methylglutaryl CoA reductase, the mechanism by which they lower triglycerides remains unknown and forms the subject of the current study. Treatment of normal rats for 4 days with simvastatin decreased serum triglycerides significantly, whereas it increased high density lipoprotein cholesterol moderately. The decrease in triglyceride concentrations after simvastatin was caused by a reduction in the amount of very low density lipoprotein particles which were of an unchanged lipid composition. Simvastatin administration increased the lipoprotein lipase mRNA and activity in adipose tissue and heart. This effect on lipoprotein lipase was accompanied by decreased mRNA as well as plasma levels of the lipoprotein lipase inhibitor apolipoprotein C‐III. These results suggest that the triglyceride‐lowering effect of statins involves a stimulation of lipoprotein lipase‐mediated clearance of triglyceride‐rich lipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Self-citationGinsberg, H. N., Le, N. A., Goldberg, I. J., Gibson, J. C., Rubinstein, A., Wang-Iverson, P., Norum, R., & Brown, W. V. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112713 · Cited by 424
Wang, X., Briggs, M. R., Hua, X., Yokoyama, C., Goldstein, J. L., & Brown, M. S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85266-3 · Cited by 299
Cited by
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J., Irvine, S., & Ramji, D. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 927
Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001854 · Cited by 388
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism
Shachter, N. S. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200106000-00009 · Cited by 288
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Ooi, E. M. M., Barrett, P. H. R., Chan, D. C., & Watts, G. F. (2008) · Clinical Science · doi:10.1042/cs20070308 · Cited by 282
Identification of Rev-erbα as a physiological repressor of apoC-III gene transcription
Raspé, E., Duez, H., Mansén, A., Fontaine, C., Fiévet, C., Fruchart, J.-C., Vennström, B., & Staels, B. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200386-jlr200 · Cited by 183
“Serum apoC-III levels were measured by an immunonephelometric assay using a specific polyclonal antibody as previously described (40).”
MethodSelf-citation
Metadata
- Authors
- Schoonjans, K., Peinado-Onsurbe, J., Fruchart, J.-C., Tailleux, A., Fiévet, C., & Auwerx, J.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 1999-06-11
- Volume
- 452
- Issue
- 3
- Pages
- 160-164
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2022158649
- Cited by
- 89
- References
- 4
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase. https://app.cochat.ai/papers/10.1016/s0014-5793(99)00632-8
- The paper
- Schoonjans, K., Peinado-Onsurbe, J., Fruchart, J.-C., Tailleux, A., Fiévet, C., & Auwerx, J. (1999). 3‐Hydroxy‐3‐methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C‐III and lipoprotein lipase. FEBS Letters. https://doi.org/10.1016/s0014-5793(99)00632-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.